Jamie Chaft, MD
Enriched profileThoracic Medical Oncologist · Memorial Sloan Kettering Cancer Center
Jamie Chaft is Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 580 publications with 32,682 citations (h-index 72); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Jamie Chaft, MD, is Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center. The public record shows 580 publications with 32,682 citations (h-index 72), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2013–2014).
- Top research focus: Lung Cancer Treatments and Mutations
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 170.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Director of Early Stage Lung Cancer Research
Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Study Chair
NCTN trial of adjuvant nivolumab, ALCHEMIST program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Co-lead
LCRF LEADER study
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 16 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments$14,345openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20251 payment
- AstraZeneca UK LimitedProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.4%Kinase inhibitor40.4%Tagrisso72%Lorbrena9%Erlotinib Hcl6%Alecensa5%Xalkori4%Tepmetko3%Part D<11 patientsMetabolism & gastrointestinal
17.9%Proton pump inhibitor6.4%Pantoprazole Sodium62%Omeprazole39%Part D≥19 patientsCorticosteroid5.6%Prednisone100%Part D≥28 patients+ 2 more classes in this area
Sensory organs
12.2%Corticosteroid10.7%Dexamethasone100%Part D≥56 patientsFluoroquinolone Antibacterial1.5%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2013–2014 per NIH RePORTER. The latest:
- Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT
Sloan-Kettering Inst Can Research
FY2014$486,303U01CA157442 - Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT
Sloan-Kettering Inst Can Research
FY2013$583,127U01CA157442
Congress activity
Updated 16 Oct 2026
94 congress contributions (2011–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Adjuvant erlotinib versus observation after complete resection of EGFR -mutant NSCLC: Final overall survival results of Alliance A081105.
ASCO Annual Meeting
ASCO2026Co-author - Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
New England Journal of Medicine
2023
Most-cited works
by citation count (OpenAlex)- 01Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,059 citations2019
- 02Neoadjuvant PD-1 Blockade in Resectable Lung CancerArticle2,095 citations2018
- 03
- 04Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyArticle1,213 citations2016
- 05Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerArticle1,155 citations2023
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jamie-chaft-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
mskcc.org/node/17510
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - YouTube
mskcc.org/videos/meet-jamie-chaft-thoracic-medical-oncologist-at-msk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vivo.weill.cornell.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center